Author:
Puglisi M,Dolly S,Faria A,Myerson J S,Popat S,O'Brien M E R
Publisher
Springer Science and Business Media LLC
Reference105 articles.
1. Amarasena IU, Walters JA, Wood-Baker R, Fong K (2008) Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev 4: CD006849
2. Ando M, Ando Y, Sekido Y, Ando M, Shimokata K, Hasegawa Y (2002) Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn J Cancer Res 93: 591–597
3. Ardizzoni A (2004) Topotecan in the treatment of recurrent small cell lung cancer: an update. Oncologist 9 (Suppl 6): 4–13
4. Argiris A, Murren JR (2001) Staging and clinical prognostic factors for small-cell lung cancer. Cancer J 7: 437–447
5. Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, Lee CW, Djurfeldt M, Whitehead M, Ellis P, Goss G, Chan A, Meharchand J, Alam Y, Gregg R, Butts C, Langmuir P, Shepherd F (2007) Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 25: 4278–4284
Cited by
95 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献